Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Could a new ADC project distract attention away from evorpacept?
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
